Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimatoprost 0.01% versus timolol 0.5% for 24-hour intraocular pressure control
2010-024272-26Phase 4Completed
- Sponsor
- Fondazione G.B. Bietti-IRCCS
- Start
- Mar 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of bimatoprost and timolol in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Fondazione G.B. Bietti-IRCCS. Primary endpoint: 24-hour mean intraocular pressure after 8 weeks. Started Mar 2012; status: completed.
02
Drugs
bimatoprosttimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2010-024272-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024272-26.